Hughes Biomedical Funding A Mixed Blessing, Some Say

And the investment has paid off--as evidenced by, among other things, HHMI researchers' prolific and influential publication record: Last year, for example, nearly one- quarter of the 200 most cited biomedical publications by U.S. scientists were authored by HHMI-affiliated investigators (see story on page 14). But despite the institute'S imposing presence and glowing achievements, some researchers and agency officials contend that

Written byKaren Kreeger
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

And the investment has paid off--as evidenced by, among other things, HHMI researchers' prolific and influential publication record: Last year, for example, nearly one- quarter of the 200 most cited biomedical publications by U.S. scientists were authored by HHMI-affiliated investigators (see story on page 14).

But despite the institute'S imposing presence and glowing achievements, some researchers and agency officials contend that certain side-effects of the HHMI program are not in the best interests of the scientific research community or the scientists themselves.

They claim, for example, that the program fosters a scientific elitism that is, as one of them puts it, "Unhealthy," especially in the current climate of stagnating or dwindling funding for biomedicine. Moreover, some HHMI appointees report that at times they have felt resentment from their colleagues--a result of what one Hughes investigator terms "the envy factor"--and, ironically, have been discriminated against when pursuing funding from other sources ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies